Melatonin
Melatonin, licence 80000711: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Biomed International Products Corp.
- NPN or DIN-HM
- 80000711
- Status
- Active licence
- Licence date
- 25 August 2005
- Revision date
- Not provided
- Form
- Liquide
- Route of administration
- Orale
- Application type
- (M) non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Méthylcellulose, Saccharin Sodium (anhydrous), Poly(sorbate) 80, Glycérine, Acide citrique
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | minimum: 1.0 millilitre ; maximum: 2.0 millilitre | 1.0 Tous les jours |
Uses authorised in Canada
Helps to increase total sleep time aspect of sleep quality in people suffering from sleep restriction or altered sleep schedule.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use if you are taking immunosupressive drugs. Do not use if pregnant or breastfeeding.
- Précautions et mises en garde
Do not drive or use machinary for 5 hours after taking melatonin. Consult a health care practitioner prior to use if you have a hormonal disorder, diabetes, liver or kidney disease, cerbral palsy, seizure disorders, migraine, depression and/or hypertension or if you are taking blood pressure or sedative/hypnotic medications. If symptoms persist continuously for more than four weeks or if pain or other factors appear to be the cause of sleeplessness, consult a health care practitioner.
Source
Official Health Canada record, licence 80000711
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.